Proteomic and clinical biomarkers for acute mountain sickness diagnosis, prognosis, protection, and pathogenesis in a longitudinal cohort

Jing Yang, Zhilong Jia, Xinyu Song, Jinlong Shi, Xiaojing Zhao, Kunlun HemedRxiv 2021 · DOI

Abstract

Acute mountain sickness (AMS) is frequently experienced by non-high-altitude natives at high altitudes, affecting health and productivity. Diagnosis currently relies on subjective self-questionnaires, highlighting a need for reliable, objective biomarkers. This study profiled plasma proteomic changes in a longitudinal cohort of 53 individuals using proximity extension assays (PEA) and multiple reaction monitoring (MRM). By integrating 65 clinical indexes and 22 symptom phenotypes, researchers identified biomarkers for AMS diagnosis, prognosis, protection, and pathogenesis. Key findings include the identification of RET and ADAM15 as potential therapeutic targets, and PHGDH and TRAF2 as candidate predictive and diagnostic biomarkers. Notably, higher baseline gluconeogenesis activity at sea level was found to predict AMS susceptibility. These results provide biological insights into AMS and promote the development of precision medicine for high-altitude conditions.

Introduction

Acute Mountain Sickness (AMS) is a common condition affecting individuals who ascend rapidly to altitudes above 2,500 meters. Symptoms range from debilitating headaches and nausea to life-threatening edema. Currently, the "gold standard" for diagnosis is the Lake Louise Score (LLS), a subjective self-questionnaire. This subjectivity complicates precise medical care and prevents the identification of high-risk individuals before ascent. This research aims to establish objective molecular markers to improve diagnosis and predict susceptibility.

Methods and Study Design

The researchers conducted a two-stage longitudinal study following 53 Chinese Han male subjects as they traveled from 1,200m (plain) to 4,300m (high altitude).

  1. Discovery Stage: Proximity Extension Assay (PEA) technology was used to screen 1,069 proteins in a subset of participants to identify differentially expressed proteins (DEPs).
  2. Validation Stage: Multiple Reaction Monitoring (MRM) validated 102 key proteins across the entire cohort (30 AMS patients, 23 non-AMS controls).
  3. Machine Learning: Four XGBoost models were developed to classify subjects based on pathogenesis, protection (resilience), prediction (pre-ascent), and diagnosis (at altitude).
Overview of the study design, biomarker identification, and machine learning classification workflow.

Key Insights and Results

Biomarkers for Clinical Scenarios

The XGBoost models demonstrated high accuracy in identifying individuals across four critical clinical contexts:

  • Pathogenesis (AUC 0.90): Identified a 7-protein panel, with RET as a top-weighted variable. RET is linked to pain-sensing neurons, potentially explaining AMS headaches.
  • Protection (AUC 0.95): Found that individuals who remained healthy (nAMS) significantly downregulated ADAM15 at high altitude, suggesting a protective role for suppressing certain inflammatory pathways.
  • Prediction (AUC 0.91): Identified PHGDH as a critical biomarker at sea level that can predict who will fall ill before they ascend.
  • Diagnosis (AUC 0.89): Utilized a 13-protein panel featuring TRAF2 and AGT to objectively diagnose AMS at altitude.

Metabolic Pre-conditioning and Networks

A major finding was that individuals susceptible to AMS already exhibited higher gluconeogenesis activity while still at sea level. This suggests that a person's baseline metabolic state is a primary determinant of altitude tolerance. Furthermore, protein-symptom-clinical index functional network analysis revealed how these molecular markers correlate with specific clinical phenotypes.

Visualization of functional enrichment, carbohydrate metabolism shifts, and the protein-clinical index network.

Discussion and Future Directions

While these findings offer a wealth of biological insights, the study has limitations. The cohort was relatively small and limited to young Han Chinese males; future research must validate these biomarkers in larger, more diverse populations. Additionally, functional in vivo experiments are needed to confirm the causal roles of proteins like RET and ADAM15. Ultimately, integrating these molecular "fingerprints" with traditional clinical scores could revolutionize the management of AMS and move the field toward true precision medicine for high-altitude health.

Summary updated

Abstract

Abstract Acute mountain sickness (AMS) is frequently experienced by non-high-altitude natives at high altitudes, which affects the quality of health and productivity of humans. The diagnosis of the disease mainly depends on a self-questionnaire, which reveals our insufficient understanding of AMS and the necessity of developing reliable biomarkers for AMS. In addition to 65 clinical indexes and 22 AMS symptom phenotypes, we profiled the plasma proteomic profiles of AMS via a combination of proximity extension assay with multiple reaction monitoring for a longitudinal cohort of 53 individuals divided into discovery and validation stages. Through differential analysis, machine learning models with high accuracy and protein-symptom-clinical index functional network analysis, we identified proteomic and clinical biomarkers for AMS diagnosis, prognosis, protection, and pathogenesis. RET, a top-weighted protein in the pathogenesis model, showed opposite regulations between individuals with AMS and those without AMS ascending to a high altitude. The downregulation of ADAM15 may play a protective role at high altitude in individuals without AMS. These results suggest that RET and ADAM15 could be promising therapeutic targets for AMS. Moreover, PHGDH and TRAF2 could be candidate predictive and diagnostic biomarkers for AMS, respectively. Additionally, C-peptide was found to be actively involved in the pathogenesis and could aid the assistant diagnosis of AMS. Notably, individuals with AMS showed higher gluconeogenesis activity at the plain than those without AMS. Our findings shed light on the proteomic and clinical biomarkers of AMS, provide a wealth of biological insights into AMS, and thereby promote precision medicine for AMS.
BibTeX
@misc{yang2021proteomic,
  author = {Jing Yang and Zhilong Jia and Xinyu Song and Jinlong Shi and Xiaojing Zhao and Kunlun He},
  title = {{Proteomic and clinical biomarkers for acute mountain sickness diagnosis, prognosis, protection, and pathogenesis in a longitudinal cohort}},
  year = {2021},
  doi = {10.1101/2021.10.18.21265176},
  howpublished = {medRxiv},
}
Figure